Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer

Table 5 Baseline hematological prognostic indicators markers for patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy, mean ± SD

Characteristics	Stats	Normal range
Height (cm)	162.6 ± 8.2	140-190
Weight (kg)	61.0 ± 8.9	40-100
ALLC (109/L)	6.1 ± 2.2	3.5-9.5
ANC (109/L)	5.9 ± 11.1	1.8-6.3
ALC (109/L)	1.6 ± 0.6	1.1-3.2
AMC (109/L)	0.4 ± 0.2	0.1-0.6
PLT (109/L)	253.5 ± 79.7	125-350
AEC (109/L)	0.3 ± 0.5	0.02-0.52
RDW (%)	14.7 ± 3.2	11.6-14.8
FIB (g/L)	3.7 ± 1.5	2-4
Dimer (ng/mL)	879.3 ± 1162.6	0-500
LDH (IU/L)	257.5 ± 150.4	109-245
ALB (g/L)	41.5 ± 4.0	40-55
CEA (ng/mL), n (%)	10 (35.7)	0-5
	18 (64.3)
CA199 (IU/mL), n (%)	19 (67.9)	0-37
	9 (32.1)

ALLC: Absolute leukocyte count; ANC: Absolute neutrophil count; ALC: Absolute lymphocyte count; AMC: Absolute monocyte count; PLT: Platelet; AEC: Absolute eosinophil count; RDW: Red blood cell distribution width; FIB: Fibrinogen; LDH: Lactate dehydrogenase; ALB: Albumin; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199.